Limited prognostic information exists for 5-to 15-year survivors. We used the Surveillance, Epidemiology, and End Results (SEER) database (http://www.seer.cancer.gov) to quantify yearly risks of death due to PDAC vs other causes and calculate CS estimates extending 21 years after diagnosis.
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Figure. Death due to any cause Death due to PDAC Death due to other causes
Cancer-specific and overall survival (A) and yearly hazards of death due to PDAC, other causes, and any cause (B). The display of the yearly hazard of death due to PDAC stops at 20.5 years because that is when the last death due to PDAC occurred. Abbreviation: CS, conditional survival. a For example, for a patient with a T1-T4N1M0 tumor who had survived for 6 years after diagnosis, the probability of surviving until 15 years after diagnosis without dying of pancreatic adenocarcinoma was 60.5% and the probability of surviving until 15 years without dying of any cause was 37.4%. Methods | The 1988-2009 SEER database was queried for patients aged 18 to 89 years with nonmetastatic PDAC with no previous cancers, at least 1 month of follow-up, and known stage. Data analysis was conducted from January 10 to February 15, 2018. Tumors were classified as T1-T2N0M0, T3-T4N0M0, and T1-T4N1M0 owing to inconsistent available stage codes. Deaths were classified as due to PDAC or other causes. The University of Utah institutional review board considers SEER studies exempt from review. Overall survival (OS) and cancer-specific survival (CSS) were evaluated using the Kaplan-Meier method. Survival was right-censored at 21 years because the last PDAC-related death occurred at 20.5 years. Smoothed yearly hazards of death due to PDAC, other causes, and any cause were evaluated graphically. Conditional survival was calculated as the probability of survival for x additional years (CS x ) given y years of accumulated survival (CS x = S (x + y) /S (y) ). Analyses were conducted with Stata, version 14.0 (StataCorp).
Results | Of 10 988 patients, 5437 (49.5%) were women, the mean (SD) age was 64.8 (10.8) years, and 8206 (74.7%) were of non-Hispanic white race/ethnicity. Tumors were in the pancreatic head in 8591 patients (78.2%). Stage was T1-T2N0M0 in 1588 patients (14.5%), T3-T4N0M0 in 2951 patients (26.9%), and T1-T4N1M0 in 6449 patients (58.7%).
Observed CSS and OS are shown in the Figure, A. Hazards of overall and PDAC-related death peaked during year 3 (Figure,  B) . Hazards of death due to other causes exceeded that of PDACrelated death by approximately 8.75 years after diagnosis. Hazards of PDAC-related mortality decreased until approximately year 13 and then remained less than 3% per year. Five PDAC-related deaths occurred after 15 years, and 2 occurred after 20 years. The CSS-and OS-based estimates of future survival increased with longer accrued survival (Table) .
Discussion | In this study, patients with resected PDAC were more likely to die of causes other than PDAC starting 8.75 years after diagnosis, but PDAC-related deaths occurred as late as 20.5 years after diagnosis. In a 2008 study, PDAC-related death occurred in 16% of 5-year survivors, but not after 7.8 years.
1 A more recent study reported recurrences in 15-year survivors. 4 The approximately 10% per year risk of death between years 9 and 15 reported here is similar to that in an NCDB study. 6 PDAC-related deaths are unlikely among 13-to 15-year survivors. Our CS estimates expand on previous studies by demonstrating that prognosis continues to improve with accrued survival beyond 5 years.
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Limitations of the study include the possibility of misclassification of cause of death, although very late PDAC-related deaths were previously reported, 4 and the fact that the survival probabilities herein are means during a 22-year period of improving outcomes. These findings may be useful to physicians responsible for advising patients with resected PDAC about their prognosis. Editor's Note
Conditional Survival as a Pragmatic Resource for Cancer Survivors and Health Care Professionals
Although there are readily available population-level data from national data sets and large clinical trials regarding the likelihood that patients with a de novo diagnosis of cancer may be alive at certain times (ie, 5 years), there is a paucity of data to guide actual cancer survivors on their estimated outcome if they have already survived a certain number of years. In fact, for patients who are followed up years after being treated for a cancer, a common scenario is for the patient and caregivers to ask practitioners what the longer term prognosis may be. The question posed to practitioners may be, "Doc, am I now cured? It's been 5 years since we finished treatment." This is an everyday practical query in the clinic. In the meantime, a currently available crude outcome prediction tool is known as conditional survival. For example, the 5-year conditional (overall and cause-specific) survival can be calculated for covariates that are included in multivariable regression models. Conditional survival is the proportion surviving, forexample, 5 additional years, per the following equation: when S(t) is (overall or cause-specific) survival at time t, conditional survival is S(× +5)/S(× Methods | We analyzed factors associated with treatment and gastric cancer care in rural western Honduras in a cohort of patients with gastric cancer in an ongoing population-based, case-control study with an endoscopy and pathology registry from 2002 through 2015. 4 The nascent population-based cancer registry data were used to assess completeness for 2013 through 2015.
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An active follow-up protocol was used in 2016 during household visits in rural and remote areas by interviewing the patient Risk factors independently associated with limited access to cancer treatment were identified using multivariate logistic regression models for cases diagnosed between 2002 and 2015. Complete data were available for 55.5% of cases. All variables included in the model are shown in the figure. The vertical line represents an odds ratio (OR) of 1.00, the reference category for factors limiting treatment access (OR, <1.00). 
